Ontology highlight
ABSTRACT:
SUBMITTER: Fattore L
PROVIDER: S-EPMC4694796 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature
Fattore Luigi L Malpicci Debora D Marra Emanuele E Belleudi Francesca F Noto Alessia A De Vitis Claudia C Pisanu Maria Elena ME Coluccia Pierpaolo P Camerlingo Rosa R Roscilli Giuseppe G Ribas Antoni A Di Napoli Arianna A Torrisi Maria Rosaria MR Aurisicchio Luigi L Ascierto Paolo Antonio PA Mancini Rita R Ciliberto Gennaro G
Oncotarget 20150901 28
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors. However, a limitation to such treatment is the occurrence of resistance. Tackling the adaptive changes helping cells survive from drug treatment may offer new therapeutic opportunities. Very recently the ErbB3 receptor has been shown to act as a central node promoting survival of BRAF mutated melanoma. In this paper we f ...[more]